Dupuis Jehan

Hématologie

Hôpital Henri Mondor
Créteil, France

216 Activités

35 Followers

Scientifique

Digital

Production scientifique

Activités par an

Expertise

Sujets de recherche

Lymphomes Leucémies Leucémie chronique lymphocytaire à cellules B Maladie de Hodgkin Leucémie lymphoïde Lymphome B Lymphome folliculaire Lymphome à cellules du manteau Lymphome B diffus à grandes cellules

Collaborateurs

Haioun Corinne

Hôpital Henri Mondor, Créteil, France

Casasnovas Rene-Olivier

Hôpital François Mitterrand, Dijon, France

Morschhauser Franck

Centre Hospitalier de Lille, Lille, France

Tilly Herve

Centre Henri-Becquerel, Rouen, France

Industries

AstraZeneca

6 collaboration(s)

Dernière en 2023

Abbvie

4 collaboration(s)

Dernière en 2023

OVERCOME

1 collaboration(s)

Dernière en 2021

{{person.topindus4.tot}} collaboration(s)

Dernière en {{person.topindus4.last}}

Dernières activités

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma: An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Essai Clinique (Acerta Pharma BV) 19 janvier 2024

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.

Haematologica 30 novembre 2023

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

65th ASH Annual Meeting Abstracts 02 novembre 2023

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.